XYNAPSE
Live / Applied — Non-final action mailed (as of 11 Mar 2026)
What this means for you
Not registered yet, but its 16 Oct 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99446868
- Mark type
- Stylized text
- Filed
- 16 Oct 2025
- Attorney of record
- Miriam D. Trudell
Goods and services
- Class 001 — Chemicals: Chemical products for diagnostic, industrial and scientific purposes; diagnostic reagents for diagnostic and scientific purposes; research reagents for scientific and diagnostic purposes; diagnostic test materials for scientific and diagnostic purposes; diagnostic kits for scientific and diagnostic purposes; assays for research and diagnostic purposes; biochemical reagents; analytical preparations for scientific purposes related to vaccines and immunotherapeutics, cancer vaccines, borrelia vaccines, tuberculosis vaccines, HIV vaccines, CMV vaccines and other vaccines, or for use in connection with therapy and immunotherapy, including cancer therapy, cancer immunotherapy, for analysis or treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and for analysis of infectious diseases and autoimmunity, and for use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring; chemical reagents
- Class 005 — Pharmaceuticals: Preparations for pharmaceutical purposes, preparations for medical purposes, chemical-pharmaceutical preparations, diagnostic preparations for medical purposes, reagents for medical and veterinary purposes; vaccines; analytical preparations for medical purposes, including for each of the above preparations for the development or analysis of vaccines, immunotherapeutics and cellular therapy, including cancer vaccines and immunotherapeutics, borrelia vaccines, tuberculosis vaccines, HIV vaccines and CMV vaccines, T-cell treatments, or for use in connection with cancer therapy or other therapy, for the analysis or treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and infectious diseases, and for use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring
Owner
- Immudex ApS, Virum, DK
Prosecution history
- 11 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 11 Mar 2026 — NON-FINAL ACTION E-MAILED
- 11 Mar 2026 — NON-FINAL ACTION WRITTEN
- 04 Mar 2026 — ASSIGNED TO EXAMINER
- 16 Oct 2025 — APPLICATION FILING RECEIPT MAILED
- 16 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 16 Oct 2025 — NEW APPLICATION ENTERED